타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Repatha (evolocumab) | Leqvio (inclisiran) | Praluent (alirocumab) |
Overview Company | Amgen | Novartis | Sanofi / Regeneron |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PCSK9 | PCSK9 (siRNA) | PCSK9 |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH | Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) | Hyperlipidemia, ASCVD, HeFH |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen | Infrequent dosing (q6 months maintenance) | Flexible q2w dosing; post-ACS outcomes label |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies | Injection-site reactions; long-term siRNA durability generally maintained. | resistance to immune checkpoint blockade |
Positioning Development positioning | Add-on to statin ± ezetimibe | — | — |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. | Inclisiran is a GalNAc-conjugated siRNA that catalytically degrades PCSK9 mRNA in hepatocytes, reducing PCSK9 protein and increasing LDLR density. | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. | LDL-C, PCSK9 protein levels. | LDL-C, ApoB. |
Toxicology Species | Cynomolgus monkey, Hamster | Mouse, Rat | Rat |
Toxicology Animal (cat.) | NHP | — | — |
Toxicology Major finding | No major organ toxicity; injection-site reactions | Injection-site reactions, arthralgia, urinary tract infection. | Injection-site reactions, flu-like symptoms. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | No major organ toxicity; injection-site reactions | Injection-site reactions, arthralgia, urinary tract infection. | Injection-site reactions, flu-like symptoms. |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | Mouse, In vitro | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Repatha (evolocumab) | Leqvio (inclisiran) | Praluent (alirocumab) |
Overview Company | Amgen | Novartis | Sanofi / Regeneron |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PCSK9 | PCSK9 (siRNA) | PCSK9 |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH | Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) | Hyperlipidemia, ASCVD, HeFH |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen | Infrequent dosing (q6 months maintenance) | Flexible q2w dosing; post-ACS outcomes label |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies | Injection-site reactions; long-term siRNA durability generally maintained. | resistance to immune checkpoint blockade |
Positioning Development positioning | Add-on to statin ± ezetimibe | — | — |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. | Inclisiran is a GalNAc-conjugated siRNA that catalytically degrades PCSK9 mRNA in hepatocytes, reducing PCSK9 protein and increasing LDLR density. | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. | LDL-C, PCSK9 protein levels. | LDL-C, ApoB. |
Toxicology Species | Cynomolgus monkey, Hamster | Mouse, Rat | Rat |
Toxicology Animal (cat.) | NHP | — | — |
Toxicology Major finding | No major organ toxicity; injection-site reactions | Injection-site reactions, arthralgia, urinary tract infection. | Injection-site reactions, flu-like symptoms. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | No major organ toxicity; injection-site reactions | Injection-site reactions, arthralgia, urinary tract infection. | Injection-site reactions, flu-like symptoms. |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | Mouse, In vitro | — | — |
추천 비교
추천 비교